Latest BioLineRx Stories
HAMPTON, N.J., July 1, 2014 /PRNewswire/ -- Bellerophon Therapeutics, LLC, a clinical stage biotherapeutics company, leveraging its proprietary drug-device technology platform for the development
JERUSALEM, March 3, 2014 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic
- BL-8040 study published in Molecular Cancer Therapeutics - JERUSALEM, Feb.
- BL-8040 previously received Orphan Drug Designation for treatment of Acute Myeloid Leukemia - JERUSALEM, Jan.
Phase 1 Trial of BL-8040 expected to begin in Q2 2014; top-line results expected in H2 2014 JERUSALEM, Jan.
- JHL Biotech to develop and commercialize BL-9020 in China and additional Southeast Asia countries - JERUSALEM and HSINCHU, Taiwan, Jan.
- Pertaining to the surface or end opposite to the mouth in a radiate animal.